Login to Your Account



As Much As $150M More Later

Astellas Buying Into Cancer; $387M Up Front For Agensys

By Randall Osborne


Wednesday, November 28, 2007
Facing patent expiration for its top-selling drug next year, the Japanese firm Astellas Pharma Inc. is buying out Agensys Inc. for $387 million up front (assuming about $30 million net cash at closing), with potentially $150 million more in milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription